$KSPHF
Hyperuricemia - Pipeline Review 2015
M2 - Wed Jan 06, 4:37AM CST
Research and Markets (http://www.researchandmarkets.com/research/rgknwq/hyperuricemia) has announced the addition of the "Hyperuricemia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hyperuricemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hyperuricemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope of the Report: - The report provides a snapshot of the global therapeutic landscape of Hyperuricemia. - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities. - The report reviews key players involved in the therapeutics development for Hyperuricemia and enlists all their major and minor projects. - The report summarizes all the dormant and discontinued pipeline projects. - A review of the Hyperuricemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages. - A detailed assessment of monotherapy and combination therapy pipeline projects. - Coverage of the Hyperuricemia pipeline on the basis of target, MoA, route of administration and molecule type. - Latest news and deals relating related to pipeline products. Companies Mentioned: - AstraZeneca Plc - CymaBay Therapeutics, Inc. - Kissei Pharmaceutical Co., Ltd. - LG Life Science LTD. - Nippon Chemiphar Co., Ltd. - Polaris Pharmaceuticals, Inc. - Selecta Biosciences, Inc. - Takeda Pharmaceutical Company Limited - Teijin Limited For more information visit http://www.researchandmarkets.com/research/rg...eruricemia
AZN: 33.97 (-0.31), CBAY: 1.95 (+0.03)
Global Kissei Pharmaceutical Co Ltd Product Pipeline Review 2015
M2 - Tue Dec 29, 3:02AM CST
AcuteMarketReports.com has announced the addition of "Global Kissei Pharmaceutical Co Ltd Product Pipeline Review 2015 "Market Research Report to their Database.
Endometriosis - Pipeline Review, H2 2015
M2 - Tue Dec 08, 3:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/cpbbkh/endometriosis) has announced the addition of the "Endometriosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Endometriosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Endometriosis and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Endometriosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Endometriosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - AbbVie Inc. - Addex Therapeutics Ltd - APAvadis Biotechnologies Srl - Astellas Pharma Inc. - Bayer AG - Dongkook Pharmaceutical Co., Ltd. - ElexoPharm GmbH - EndoCeutics, Inc. - Enteris BioPharma, Inc. - Euroscreen S.A. - Evotec AG - Forendo Pharma Oy - GlaxoSmithKline Plc - Kissei Pharmaceutical Co., Ltd. - Lipicard Technologies Limited - Nippon Shinyaku Co., Ltd. - Orphagen Pharmaceuticals, Inc. - Philogen S.p.A. - Repros Therapeutics Inc. - SK Chemicals Co., Ltd. - Takeda Pharmaceutical Company Limited - ValiRx Plc For more information visit http://www.researchandmarkets.com/research/cp...ometriosis.
ABBV: 64.98 (-0.10), GSK: 43.42 (-0.16)
Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H2 2015
M2 - Mon Nov 09, 9:44AM CST
Research and Markets (http://www.researchandmarkets.com/research/ttwz6m/keratoconjunctivit) has announced the addition of the "Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Keratoconjunctivitis sicca (Dry Eye), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Keratoconjunctivitis sicca (Dry Eye) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Allergan Plc - Celsus Therapeutics Plc - Circadian Technologies Limited - Digna Biotech, S.L. - Dompe Farmaceutici S.p.A. - HanAll Biopharma Co., Ltd. - Herantis Pharma plc. - Huons Co., Ltd. - InSite Vision Incorporated - Kala Pharmaceuticals, Inc. - Kissei Pharmaceutical Co., Ltd. - Laboratorios Sophia S.A. de C.V. - Lee's Pharmaceutical Holdings Limited - Lipicard Technologies Limited - LTT Bio-Pharma Co., Ltd. - Merck & Co., Inc. - Mimetogen Pharmaceuticals Inc. - Nanomerics Ltd - Neuroptis Biotech - Novaliq GmbH - Ocular Therapeutix, Inc. - OncoNOx ApS - Otsuka Holdings Co., Ltd. - Parion Sciences, Inc. - R-Tech Ueno, Ltd. - RegeneRx Biopharmaceuticals, Inc. - Resolvyx Pharmaceuticals, Inc - Rigel Pharmaceuticals, Inc. - Samjin Pharmaceutical Co., Ltd. - Santen Pharmaceutical Co., Ltd. - Scynexis, Inc. - Seikagaku Corporation - Shire Plc - TearSolutions, LLC. - Vertex Pharmaceuticals Incorporated For more information visit http://www.researchandmarkets.com/research/tt...njunctivit
VRTX: 90.63 (-1.49), RIGL: 3.44 (-0.01), OCUL: 7.14 (-0.04), AGN: 243.94 (+0.51), SHPG: 203.05 (-1.17), MRK: 62.96 (-0.06)
Global Constipation Pipeline Review 2015 - 16 Companies & 18 Drug Profiles
M2 - Tue Sep 08, 6:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/b5h9s9/constipation) has announced the addition of the "Constipation - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Constipation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Constipation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AlbireoPharma - Ardelyx, Inc. - Astellas Pharma Inc. - Braintree Laboratories, Inc. - Daiichi Sankyo Company, Limited - Dong-A Socio Group - Ironwood Pharmaceuticals, Inc. - Kissei Pharmaceutical Co., Ltd. - RaQualia Pharma Inc. - Rhythm Pharmaceuticals - Sanwa Kagaku Kenkyusho Co., Ltd. - Shire Plc - SK Biopharmaceuticals Co., Ltd. - Sucampo Pharmaceuticals, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - Synergy Pharmaceuticals, Inc. Drug Profiles - ASP-7663 - BLI-400 - DA-6886 - DS-3801 - DSP-6952 - elobixibat - KWA-0711 - linaclotide - lubiprostone - plecanatide - prucalopride succinate - relamorelin - relenopride hydrochloride - RQ-00000010 - SK-1202 - Small Molecule to Activate 5-HT1 Receptor for Constipation and Dyspepsia - tenapanor hydrochloride - Transilon For more information visit http://www.researchandmarkets.com/research/b5...nstipation
SGYP: 5.61 (+0.03), IRWD: 15.72 (-0.15), SHPG: 203.05 (-1.17), SCMP: 13.23 (-0.15)
Spinocerebellar Ataxias Pipeline Review, H1 2015 - 4 Companies & 5 Drug Profiles
M2 - Tue Jul 28, 9:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l57jb6/spinocerebellar) has announced the addition of the "Spinocerebellar Ataxias - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Spinocerebellar Ataxias, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Spinocerebellar Ataxias and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Baxter International Inc. - Bioblast Pharma Ltd. - Kissei Pharmaceutical Co., Ltd. - Vybion, Inc. Drug Profiles - epoetin alfa - immune globulin (human) - INT-41 - KPS-0373 - RNAi Gene Therapy for Machado-Joseph Disease For more information visit http://www.researchandmarkets.com/research/l5...cerebellar
BAX: 47.49 (-0.71)
Gouty Arthritis (Gout) Pipeline Review, H1 2015 - 20 Companies & 37 Drug Profiles
M2 - Thu Jul 09, 8:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7zcbqd/gouty_arthritis) has announced the addition of the "Gouty Arthritis (Gout) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Gouty Arthritis (Gout), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gouty Arthritis (Gout) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - Celtaxsys, Inc. - CymaBay Therapeutics, Inc. - Delenex Therapeutics AG - Immune Response BioPharma, Inc. - IOmet Pharma - JW Pharmaceutical Corporation - Kissei Pharmaceutical Co., Ltd. - LG Life Sciences, Ltd. - Nimbus Therapeutics, LLC - Nippon Chemiphar Co., Ltd. - Omni Bio Pharmaceutical Inc. - Opsona Therapeutics Ltd. - PLx Pharma Inc. - Polaris Pharmaceuticals, Inc. - Selecta Biosciences, Inc. - Takeda Pharmaceutical Company Limited - Teijin Pharma Limited - TWi Pharmaceuticals, Inc. - Wellstat Therapeutics Corporation For more information visit http://www.researchandmarkets.com/research/7z..._arthritis
AZN: 33.97 (-0.31), CBAY: 1.95 (+0.03)
Global Premature Labor (Tocolysis) Pipeline Review, H1 2015 - 4 Companies & 8 Drug Profiles
M2 - Mon Jun 08, 9:41AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qhmn3k/premature_labor) has announced the addition of the "Premature Labor (Tocolysis) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Premature Labor (Tocolysis), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Premature Labor (Tocolysis) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Actavis plc - GlaxoSmithKline plc - Kissei Pharmaceutical Co., Ltd. - ObsEva SA Drug Profiles - AT-814 - bedoradrine sulfate - Drug for Postpartum Depression and Premature Labor - OBE-001 - OBE-002 - Progesterone Second Generation - retosiban - Small Molecule to Agonize Progesterone Receptor for Preterm Birth For more information visit http://www.researchandmarkets.com/research/qh...ture_labor
GSK: 43.42 (-0.16)
Hyperuricemia - Pipeline Review, H1 2015
M2 - Fri Jun 05, 9:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7s7l4f/hyperuricemia) has announced the addition of the "Hyperuricemia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hyperuricemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hyperuricemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - CymaBay Therapeutics, Inc. - Kissei Pharmaceutical Co., Ltd. - LG Life Sciences, Ltd. - Nippon Chemiphar Co., Ltd. - Polaris Pharmaceuticals, Inc. - Takeda Pharmaceutical Company Limited - Teijin Pharma Limited Drug Profiles - arhalofenate - febuxostat - febuxostat XR - JPH-367 - KGO-2142 - KGO-2173 - KUX-1151 - LC-350189 - NC-2500 - pegadricase - RDEA-3170 - Small Molecule to Inhibit Xanthine Oxidase for Gout and Hyperuricemia - Small Molecule to Inhibit Xanthine Oxidase for Hyperuricemia - XEN-102 For more information visit http://www.researchandmarkets.com/research/7s...eruricemia
AZN: 33.97 (-0.31), CBAY: 1.95 (+0.03)
Women Infertility Pipeline Review, H1 2015
M2 - Fri Jun 05, 4:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wh93bq/women_infertility) has announced the addition of the "Women Infertility - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Women Infertility, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Women Infertility and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Actavis plc - Addex Therapeutics Ltd - AlphaMab Co., Ltd - APAvadis Biotechnologies Srl - ASKA Pharmaceutical Co., Ltd. - Astellas Pharma Inc. - AstraZeneca PLC - Bayer AG - Crinetics Pharmaceuticals, Inc. - Dong-A Socio Group - Dongkook Pharmaceutical Co., Ltd. - EffRx Pharmaceuticals S.A. - ElexoPharm GmbH - EndoCeutics, Inc. - Euroscreen S.A. - Evotec AG - Ferring International Center S.A. - Finox AG - Forendo Pharma Oy - GlaxoSmithKline plc - Glycotope GmbH - Isifer AB - Kissei Pharmaceutical Co., Ltd. - Lipicard Technologies Limited - Merck & Co., Inc. - Merck KGaA - Neurocrine Biosciences, Inc. - Nora Therapeutics, Inc. - ObsEva SA - Orphagen Pharmaceuticals, Inc. - Pantec Biosolutions AG - PharmaEssentia Corporation - Philogen S.p.A. For more information visit http://www.researchandmarkets.com/research/wh...nfertility
NBIX: 53.94 (-0.22), MRK: 62.96 (-0.06), AZN: 33.97 (-0.31), ABBV: 64.98 (-0.10), GSK: 43.42 (-0.16)
Global Obesity Therapeutics Pipeline Review 2015 - Featuring 94 Companies
M2 - Wed Mar 18, 7:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c5sqxq/obesity) has announced the addition of the "Obesity - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Obesity, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Obesity and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Obesity Overview - Therapeutics Development - Obesity - Therapeutics under Development by Companies - Obesity - Therapeutics under Investigation by Universities/Institutes - Obesity - Pipeline Products Glance - Obesity - Products under Development by Companies - Obesity - Products under Investigation by Universities/Institutes - Obesity - Companies Involved in Therapeutics Development - Obesity - Therapeutics Assessment - Drug Profiles - Obesity - Recent Pipeline Updates - Obesity - Dormant Projects - Obesity - Discontinued Products - Obesity - Product Development Milestones - Appendix Companies Mentioned - Advinus Therapeutics Ltd. - Amgen Inc. - Eli Lilly and Company - Esperion Therapeutics, Inc. - Euroscreen S.A. - F. Hoffmann-La Roche Ltd. - Galapagos NV - Galenea Corp. - Genfit SA - GlaxoSmithKline plc - GTx, Inc. - Handok Inc. - Hanmi Pharmaceuticals, Co. Ltd. - Helsinn Healthcare S.A. - High Point Pharmaceuticals, LLC - Insusense Therapeutics ApS - Intarcia Therapeutics, Inc. - Isis Pharmaceuticals, Inc. - Jenrin Discovery, Inc. - Johnson & Johnson - Kainos Medicine, Inc. - Kissei Pharmaceutical Co., Ltd. - Lead Discovery Center GmbH - LG Life Sciences, Ltd. - Mitsubishi Tanabe Pharma Corporation - Molecular Design International, Inc. - Neothetics, Inc. - P2D Bioscience - Pfizer Inc. - PharmaIN Corporation For more information visit http://www.researchandmarkets.com/research/c5sqxq/obesity
JNJ: 118.81 (-0.65), GTXI: 0.77 (+0.01), ESPR: 13.56 (-0.34), PFE: 34.26 (+0.11), NEOT: 1.22 (-0.03), AMGN: 174.80 (-0.82), LLY: 81.16 (-0.13), GSK: 43.42 (-0.16)
Premature Labor (Tocolysis) Therapeutic Pipeline Drugs and Companies Review H1 2015 Research Report Available at RnRMarketResearch.com
PRWeb - Thu Mar 12, 10:31PM CDT
The report "Premature Labor (Tocolysis) - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Male Hypogonadism. Premature Labor (Tocolysis) is labor that begins more than three weeks before you are expected to deliver your baby (but after the 24th week of pregnancy). If symptoms appear before 24 weeks, this is a threatened miscarriage and not preterm labour. The symptoms of Premature Labor (Tocolysis) include regular contractions for an hour, leaking or gushing of fluid from vagina, pain that feels like menstrual cramps, with or without diarrhea and a feeling of pressure in your pelvis or lower belly. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/premature-la...eport.html .
GSK: 43.42 (-0.16)
Constipation Therapeutics Pipeline Review 2015 - 18 Drug Profiles & 20 Drug Profiles
M2 - Tue Mar 03, 6:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/kxwf5r/constipation) has announced the addition of the "Constipation - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Constipation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Constipation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AlbireoPharma - Astellas Pharma Inc. - AstraZeneca PLC - Beech Tree Labs, Inc. - Braintree Laboratories, Inc. - Daiichi Sankyo Company, Limited - Dong-A Socio Group - Ironwood Pharmaceuticals, Inc. - Kissei Pharmaceutical Co., Ltd. - Lipid Pharmaceuticals ehf. - Rhythm Pharmaceuticals - Sanwa Kagaku Kenkyusho Co., Ltd. - Shire Plc - SK Biopharmaceuticals Co., Ltd. - Sucampo Pharmaceuticals, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - Synergy Pharmaceuticals, Inc. - Teva Pharmaceutical Industries Limited Drug Profiles - 5-BOIP - ASP-7663 - BLI-801 - DA-6886 - DS-3801 - DSP-6952 - elobixibat - KWA-0711 - linaclotide - LP-101 - lubiprostone - MDT-006 - plecanatide - prucalopride succinate - relamorelin - SK-1202 - Small Molecule for Chronic Constipation - tenapanor hydrochloride - Transilon - YKP-10811 For more information visit http://www.researchandmarkets.com/research/kx...nstipation
SGYP: 5.61 (+0.03), IRWD: 15.72 (-0.15), SHPG: 203.05 (-1.17), AZN: 33.97 (-0.31), SCMP: 13.23 (-0.15), TEVA: 51.47 (+0.24)
Non-Alcoholic Steatohepatitis Therapeutics Pipeline Review 2015 - Analysis of 32 Companies & 53 Drug Profiles
M2 - Tue Mar 03, 5:10AM CST
Research and Markets (http://www.researchandmarkets.com/research/np53sj/nonalcoholic) has announced the addition of the "Non-Alcoholic Steatohepatitis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Non-Alcoholic Steatohepatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non-Alcoholic Steatohepatitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Cardax Pharmaceuticals, Inc. - Conatus Pharmaceuticals Inc. - Connexios Life Sciences Pvt. Ltd. - Cubist Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - Dr. Falk Pharma GmbH - Dynavax Technologies Corporation - Galectin Therapeutics, Inc. - Galmed International Ltd. - Genfit SA - Gilead Sciences, Inc. - Immuron Limited - Intercept Pharmaceuticals, Inc. - Isis Pharmaceuticals, Inc. - Jenrin Discovery, Inc. - Kadmon Corporation, LLC - Kissei Pharmaceutical Co., Ltd. - Kyorin Pharmaceutical Co., Ltd. - La Jolla Pharmaceutical Company - Mochida Pharmaceutical Co., Ltd. - Novo Nordisk A/S - Pharmaxis Limited - Phenex Pharmaceuticals AG - ProMetic Life Sciences Inc. - Raptor Pharmaceuticals Corp. - Shire Plc - Stelic Institute & Co. - Tobira Therapeutics, Inc. - Verva Pharmaceuticals Limited For more information visit http://www.researchandmarkets.com/research/np...nalcoholic
DVAX: 11.41 (-0.21), CNAT: 2.11 (-0.05), GALT: 2.73 (-0.14), NVO: 44.88 (-0.69), RPTP: 9.00 (+0.03), GILD: 81.37 (-0.15), SHPG: 203.05 (-1.17), ICPT: 166.23 (-4.24), TBRA: 39.11 (-0.39)
Dyslipidemia Therapeutics Pipeline Review 2015 - 35 Companies & 49 Drug Profiles
M2 - Mon Mar 02, 10:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/4qp3rm/dyslipidemia) has announced the addition of the "Dyslipidemia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Dyslipidemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dyslipidemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amgen Inc. - Arisaph Pharmaceuticals, Inc. - AstraZeneca PLC - Biocon Limited - Cadila Pharmaceuticals Ltd. - Cerenis Therapeutics Holding SA - Chong Kun Dang Pharmaceutical Corp. - CymaBay Therapeutics, Inc. - Daiichi Sankyo Company, Limited - Debiopharm International S.A. - Dezima Pharma BV - Dr. Reddy's Laboratories Limited - Genfit SA - GlaxoSmithKline plc - Hanmi Pharmaceuticals, Co. Ltd. - High Point Pharmaceuticals, LLC - Intas Pharmaceuticals Ltd. - JW Pharmaceutical Corporation - Kissei Pharmaceutical Co., Ltd. - Kotobuki Pharmaceutical Co., Ltd. - Kowa Company, Ltd. - Lipicard Technologies Limited - Merck & Co., Inc. - Nippon Chemiphar Co., Ltd. - Novartis AG - Pfizer Inc. - Sanofi - Takeda Pharmaceutical Company Limited - Torrent Pharmaceuticals Limited - Zydus Cadila Healthcare Limited For more information visit http://www.researchandmarkets.com/research/4q...slipidemia
PFE: 34.26 (+0.11), AMGN: 174.80 (-0.82), GSK: 43.42 (-0.16), AZN: 33.97 (-0.31), MRK: 62.96 (-0.06), CBAY: 1.95 (+0.03), NVS: 81.48 (-0.55)
Dyslipidemia Therapeutic Pipeline Companies and Drugs Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Tue Jan 27, 10:31AM CST
The report provides comprehensive information on the therapeutic development for Dyslipidemia. Dyslipidemia is an abnormal amount of cholesterol or fat in the blood. Dyslipidemia comes under consideration in many situations including diabetes, a common cause of lipidemia. Dyslipidemia is one of the major risk factors for cardiovascular disease in diabetes mellitus. Complete report is available at http://www.rnrmarketresearch.com/glaucoma-pip...eport.html .
PFE: 34.26 (+0.11), MRK: 62.96 (-0.06), AZN: 33.97 (-0.31), CBAY: 1.95 (+0.03), NVS: 81.48 (-0.55)
Constipation Therapeutic Pipeline Companies and Drugs Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Sun Jan 25, 10:30AM CST
The report "Constipation - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Constipation. Constipation is a disorder in which a person has severe problems defecating. Constipation occurs primarily because of the lack of the bowel movement in the body. The Lack of bowel movement in the body results in hardening of stools, swollen abdomen or abdominal pain. The reasons for constipation to occur in a body are inadequate water intake, less proportion of fiber in diet, irregularities in the pattern of diet. Not maintaining proper health and inadequacy in exercise can also lead to the abnormality during defecation & would mostly end with painful symptoms. Complete Report is Available @ http://www.rnrmarketresearch.com/constipation...eport.html .
SGYP: 5.61 (+0.03), SHPG: 203.05 (-1.17), AZN: 33.97 (-0.31), SCMP: 13.23 (-0.15), TEVA: 51.47 (+0.24)
Premature Labor (Tocolysis) Therapeutics Pipeline Review, H2 2014 - 5 Companies & 9 Drug Profiles
M2 - Fri Nov 07, 5:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/g6q4hn/premature_labor) has announced the addition of the "Premature Labor (Tocolysis) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Premature Labor (Tocolysis), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Premature Labor (Tocolysis) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - GlaxoSmithKline plc - Actavis plc - Kissei Pharmaceutical Co., Ltd. - PDC Biotech GmbH - ObsEva SA Drug Profiles - retosiban - bedoradrine sulfate - PDC-31 - Progesterone Vaginal Gel Second Generation - OBE-001 - Progesterone Based Formulation For Preterm Birth - OBE-002 - AT-814 - Drug for Postpartum Depression and Premature Labor For more information visit http://www.researchandmarkets.com/research/g6...ture_labor
GSK: 43.42 (-0.16)
Hyperuricemia - Pipeline Review 2015
M2 - Wed Jan 06, 4:37AM CST
Research and Markets (http://www.researchandmarkets.com/research/rgknwq/hyperuricemia) has announced the addition of the "Hyperuricemia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hyperuricemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hyperuricemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope of the Report: - The report provides a snapshot of the global therapeutic landscape of Hyperuricemia. - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities. - The report reviews key players involved in the therapeutics development for Hyperuricemia and enlists all their major and minor projects. - The report summarizes all the dormant and discontinued pipeline projects. - A review of the Hyperuricemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages. - A detailed assessment of monotherapy and combination therapy pipeline projects. - Coverage of the Hyperuricemia pipeline on the basis of target, MoA, route of administration and molecule type. - Latest news and deals relating related to pipeline products. Companies Mentioned: - AstraZeneca Plc - CymaBay Therapeutics, Inc. - Kissei Pharmaceutical Co., Ltd. - LG Life Science LTD. - Nippon Chemiphar Co., Ltd. - Polaris Pharmaceuticals, Inc. - Selecta Biosciences, Inc. - Takeda Pharmaceutical Company Limited - Teijin Limited For more information visit http://www.researchandmarkets.com/research/rg...eruricemia
AZN: 33.97 (-0.31), CBAY: 1.95 (+0.03)
Global Kissei Pharmaceutical Co Ltd Product Pipeline Review 2015
M2 - Tue Dec 29, 3:02AM CST
AcuteMarketReports.com has announced the addition of "Global Kissei Pharmaceutical Co Ltd Product Pipeline Review 2015 "Market Research Report to their Database.
Endometriosis - Pipeline Review, H2 2015
M2 - Tue Dec 08, 3:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/cpbbkh/endometriosis) has announced the addition of the "Endometriosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Endometriosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Endometriosis and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Endometriosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Endometriosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - AbbVie Inc. - Addex Therapeutics Ltd - APAvadis Biotechnologies Srl - Astellas Pharma Inc. - Bayer AG - Dongkook Pharmaceutical Co., Ltd. - ElexoPharm GmbH - EndoCeutics, Inc. - Enteris BioPharma, Inc. - Euroscreen S.A. - Evotec AG - Forendo Pharma Oy - GlaxoSmithKline Plc - Kissei Pharmaceutical Co., Ltd. - Lipicard Technologies Limited - Nippon Shinyaku Co., Ltd. - Orphagen Pharmaceuticals, Inc. - Philogen S.p.A. - Repros Therapeutics Inc. - SK Chemicals Co., Ltd. - Takeda Pharmaceutical Company Limited - ValiRx Plc For more information visit http://www.researchandmarkets.com/research/cp...ometriosis.
ABBV: 64.98 (-0.10), GSK: 43.42 (-0.16)
Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H2 2015
M2 - Mon Nov 09, 9:44AM CST
Research and Markets (http://www.researchandmarkets.com/research/ttwz6m/keratoconjunctivit) has announced the addition of the "Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Keratoconjunctivitis sicca (Dry Eye), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Keratoconjunctivitis sicca (Dry Eye) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Allergan Plc - Celsus Therapeutics Plc - Circadian Technologies Limited - Digna Biotech, S.L. - Dompe Farmaceutici S.p.A. - HanAll Biopharma Co., Ltd. - Herantis Pharma plc. - Huons Co., Ltd. - InSite Vision Incorporated - Kala Pharmaceuticals, Inc. - Kissei Pharmaceutical Co., Ltd. - Laboratorios Sophia S.A. de C.V. - Lee's Pharmaceutical Holdings Limited - Lipicard Technologies Limited - LTT Bio-Pharma Co., Ltd. - Merck & Co., Inc. - Mimetogen Pharmaceuticals Inc. - Nanomerics Ltd - Neuroptis Biotech - Novaliq GmbH - Ocular Therapeutix, Inc. - OncoNOx ApS - Otsuka Holdings Co., Ltd. - Parion Sciences, Inc. - R-Tech Ueno, Ltd. - RegeneRx Biopharmaceuticals, Inc. - Resolvyx Pharmaceuticals, Inc - Rigel Pharmaceuticals, Inc. - Samjin Pharmaceutical Co., Ltd. - Santen Pharmaceutical Co., Ltd. - Scynexis, Inc. - Seikagaku Corporation - Shire Plc - TearSolutions, LLC. - Vertex Pharmaceuticals Incorporated For more information visit http://www.researchandmarkets.com/research/tt...njunctivit
VRTX: 90.63 (-1.49), RIGL: 3.44 (-0.01), OCUL: 7.14 (-0.04), AGN: 243.94 (+0.51), SHPG: 203.05 (-1.17), MRK: 62.96 (-0.06)
Global Constipation Pipeline Review 2015 - 16 Companies & 18 Drug Profiles
M2 - Tue Sep 08, 6:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/b5h9s9/constipation) has announced the addition of the "Constipation - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Constipation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Constipation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AlbireoPharma - Ardelyx, Inc. - Astellas Pharma Inc. - Braintree Laboratories, Inc. - Daiichi Sankyo Company, Limited - Dong-A Socio Group - Ironwood Pharmaceuticals, Inc. - Kissei Pharmaceutical Co., Ltd. - RaQualia Pharma Inc. - Rhythm Pharmaceuticals - Sanwa Kagaku Kenkyusho Co., Ltd. - Shire Plc - SK Biopharmaceuticals Co., Ltd. - Sucampo Pharmaceuticals, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - Synergy Pharmaceuticals, Inc. Drug Profiles - ASP-7663 - BLI-400 - DA-6886 - DS-3801 - DSP-6952 - elobixibat - KWA-0711 - linaclotide - lubiprostone - plecanatide - prucalopride succinate - relamorelin - relenopride hydrochloride - RQ-00000010 - SK-1202 - Small Molecule to Activate 5-HT1 Receptor for Constipation and Dyspepsia - tenapanor hydrochloride - Transilon For more information visit http://www.researchandmarkets.com/research/b5...nstipation
SGYP: 5.61 (+0.03), IRWD: 15.72 (-0.15), SHPG: 203.05 (-1.17), SCMP: 13.23 (-0.15)
Spinocerebellar Ataxias Pipeline Review, H1 2015 - 4 Companies & 5 Drug Profiles
M2 - Tue Jul 28, 9:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l57jb6/spinocerebellar) has announced the addition of the "Spinocerebellar Ataxias - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Spinocerebellar Ataxias, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Spinocerebellar Ataxias and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Baxter International Inc. - Bioblast Pharma Ltd. - Kissei Pharmaceutical Co., Ltd. - Vybion, Inc. Drug Profiles - epoetin alfa - immune globulin (human) - INT-41 - KPS-0373 - RNAi Gene Therapy for Machado-Joseph Disease For more information visit http://www.researchandmarkets.com/research/l5...cerebellar
BAX: 47.49 (-0.71)
Gouty Arthritis (Gout) Pipeline Review, H1 2015 - 20 Companies & 37 Drug Profiles
M2 - Thu Jul 09, 8:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7zcbqd/gouty_arthritis) has announced the addition of the "Gouty Arthritis (Gout) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Gouty Arthritis (Gout), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gouty Arthritis (Gout) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - Celtaxsys, Inc. - CymaBay Therapeutics, Inc. - Delenex Therapeutics AG - Immune Response BioPharma, Inc. - IOmet Pharma - JW Pharmaceutical Corporation - Kissei Pharmaceutical Co., Ltd. - LG Life Sciences, Ltd. - Nimbus Therapeutics, LLC - Nippon Chemiphar Co., Ltd. - Omni Bio Pharmaceutical Inc. - Opsona Therapeutics Ltd. - PLx Pharma Inc. - Polaris Pharmaceuticals, Inc. - Selecta Biosciences, Inc. - Takeda Pharmaceutical Company Limited - Teijin Pharma Limited - TWi Pharmaceuticals, Inc. - Wellstat Therapeutics Corporation For more information visit http://www.researchandmarkets.com/research/7z..._arthritis
AZN: 33.97 (-0.31), CBAY: 1.95 (+0.03)
Global Premature Labor (Tocolysis) Pipeline Review, H1 2015 - 4 Companies & 8 Drug Profiles
M2 - Mon Jun 08, 9:41AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qhmn3k/premature_labor) has announced the addition of the "Premature Labor (Tocolysis) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Premature Labor (Tocolysis), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Premature Labor (Tocolysis) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Actavis plc - GlaxoSmithKline plc - Kissei Pharmaceutical Co., Ltd. - ObsEva SA Drug Profiles - AT-814 - bedoradrine sulfate - Drug for Postpartum Depression and Premature Labor - OBE-001 - OBE-002 - Progesterone Second Generation - retosiban - Small Molecule to Agonize Progesterone Receptor for Preterm Birth For more information visit http://www.researchandmarkets.com/research/qh...ture_labor
GSK: 43.42 (-0.16)
Hyperuricemia - Pipeline Review, H1 2015
M2 - Fri Jun 05, 9:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7s7l4f/hyperuricemia) has announced the addition of the "Hyperuricemia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hyperuricemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hyperuricemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - CymaBay Therapeutics, Inc. - Kissei Pharmaceutical Co., Ltd. - LG Life Sciences, Ltd. - Nippon Chemiphar Co., Ltd. - Polaris Pharmaceuticals, Inc. - Takeda Pharmaceutical Company Limited - Teijin Pharma Limited Drug Profiles - arhalofenate - febuxostat - febuxostat XR - JPH-367 - KGO-2142 - KGO-2173 - KUX-1151 - LC-350189 - NC-2500 - pegadricase - RDEA-3170 - Small Molecule to Inhibit Xanthine Oxidase for Gout and Hyperuricemia - Small Molecule to Inhibit Xanthine Oxidase for Hyperuricemia - XEN-102 For more information visit http://www.researchandmarkets.com/research/7s...eruricemia
AZN: 33.97 (-0.31), CBAY: 1.95 (+0.03)
Women Infertility Pipeline Review, H1 2015
M2 - Fri Jun 05, 4:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wh93bq/women_infertility) has announced the addition of the "Women Infertility - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Women Infertility, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Women Infertility and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Actavis plc - Addex Therapeutics Ltd - AlphaMab Co., Ltd - APAvadis Biotechnologies Srl - ASKA Pharmaceutical Co., Ltd. - Astellas Pharma Inc. - AstraZeneca PLC - Bayer AG - Crinetics Pharmaceuticals, Inc. - Dong-A Socio Group - Dongkook Pharmaceutical Co., Ltd. - EffRx Pharmaceuticals S.A. - ElexoPharm GmbH - EndoCeutics, Inc. - Euroscreen S.A. - Evotec AG - Ferring International Center S.A. - Finox AG - Forendo Pharma Oy - GlaxoSmithKline plc - Glycotope GmbH - Isifer AB - Kissei Pharmaceutical Co., Ltd. - Lipicard Technologies Limited - Merck & Co., Inc. - Merck KGaA - Neurocrine Biosciences, Inc. - Nora Therapeutics, Inc. - ObsEva SA - Orphagen Pharmaceuticals, Inc. - Pantec Biosolutions AG - PharmaEssentia Corporation - Philogen S.p.A. For more information visit http://www.researchandmarkets.com/research/wh...nfertility
NBIX: 53.94 (-0.22), MRK: 62.96 (-0.06), AZN: 33.97 (-0.31), ABBV: 64.98 (-0.10), GSK: 43.42 (-0.16)
Global Obesity Therapeutics Pipeline Review 2015 - Featuring 94 Companies
M2 - Wed Mar 18, 7:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c5sqxq/obesity) has announced the addition of the "Obesity - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Obesity, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Obesity and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Obesity Overview - Therapeutics Development - Obesity - Therapeutics under Development by Companies - Obesity - Therapeutics under Investigation by Universities/Institutes - Obesity - Pipeline Products Glance - Obesity - Products under Development by Companies - Obesity - Products under Investigation by Universities/Institutes - Obesity - Companies Involved in Therapeutics Development - Obesity - Therapeutics Assessment - Drug Profiles - Obesity - Recent Pipeline Updates - Obesity - Dormant Projects - Obesity - Discontinued Products - Obesity - Product Development Milestones - Appendix Companies Mentioned - Advinus Therapeutics Ltd. - Amgen Inc. - Eli Lilly and Company - Esperion Therapeutics, Inc. - Euroscreen S.A. - F. Hoffmann-La Roche Ltd. - Galapagos NV - Galenea Corp. - Genfit SA - GlaxoSmithKline plc - GTx, Inc. - Handok Inc. - Hanmi Pharmaceuticals, Co. Ltd. - Helsinn Healthcare S.A. - High Point Pharmaceuticals, LLC - Insusense Therapeutics ApS - Intarcia Therapeutics, Inc. - Isis Pharmaceuticals, Inc. - Jenrin Discovery, Inc. - Johnson & Johnson - Kainos Medicine, Inc. - Kissei Pharmaceutical Co., Ltd. - Lead Discovery Center GmbH - LG Life Sciences, Ltd. - Mitsubishi Tanabe Pharma Corporation - Molecular Design International, Inc. - Neothetics, Inc. - P2D Bioscience - Pfizer Inc. - PharmaIN Corporation For more information visit http://www.researchandmarkets.com/research/c5sqxq/obesity
JNJ: 118.81 (-0.65), GTXI: 0.77 (+0.01), ESPR: 13.56 (-0.34), PFE: 34.26 (+0.11), NEOT: 1.22 (-0.03), AMGN: 174.80 (-0.82), LLY: 81.16 (-0.13), GSK: 43.42 (-0.16)
Premature Labor (Tocolysis) Therapeutic Pipeline Drugs and Companies Review H1 2015 Research Report Available at RnRMarketResearch.com
PRWeb - Thu Mar 12, 10:31PM CDT
The report "Premature Labor (Tocolysis) - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Male Hypogonadism. Premature Labor (Tocolysis) is labor that begins more than three weeks before you are expected to deliver your baby (but after the 24th week of pregnancy). If symptoms appear before 24 weeks, this is a threatened miscarriage and not preterm labour. The symptoms of Premature Labor (Tocolysis) include regular contractions for an hour, leaking or gushing of fluid from vagina, pain that feels like menstrual cramps, with or without diarrhea and a feeling of pressure in your pelvis or lower belly. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/premature-la...eport.html .
GSK: 43.42 (-0.16)
Constipation Therapeutics Pipeline Review 2015 - 18 Drug Profiles & 20 Drug Profiles
M2 - Tue Mar 03, 6:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/kxwf5r/constipation) has announced the addition of the "Constipation - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Constipation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Constipation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AlbireoPharma - Astellas Pharma Inc. - AstraZeneca PLC - Beech Tree Labs, Inc. - Braintree Laboratories, Inc. - Daiichi Sankyo Company, Limited - Dong-A Socio Group - Ironwood Pharmaceuticals, Inc. - Kissei Pharmaceutical Co., Ltd. - Lipid Pharmaceuticals ehf. - Rhythm Pharmaceuticals - Sanwa Kagaku Kenkyusho Co., Ltd. - Shire Plc - SK Biopharmaceuticals Co., Ltd. - Sucampo Pharmaceuticals, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - Synergy Pharmaceuticals, Inc. - Teva Pharmaceutical Industries Limited Drug Profiles - 5-BOIP - ASP-7663 - BLI-801 - DA-6886 - DS-3801 - DSP-6952 - elobixibat - KWA-0711 - linaclotide - LP-101 - lubiprostone - MDT-006 - plecanatide - prucalopride succinate - relamorelin - SK-1202 - Small Molecule for Chronic Constipation - tenapanor hydrochloride - Transilon - YKP-10811 For more information visit http://www.researchandmarkets.com/research/kx...nstipation
SGYP: 5.61 (+0.03), IRWD: 15.72 (-0.15), SHPG: 203.05 (-1.17), AZN: 33.97 (-0.31), SCMP: 13.23 (-0.15), TEVA: 51.47 (+0.24)
Non-Alcoholic Steatohepatitis Therapeutics Pipeline Review 2015 - Analysis of 32 Companies & 53 Drug Profiles
M2 - Tue Mar 03, 5:10AM CST
Research and Markets (http://www.researchandmarkets.com/research/np53sj/nonalcoholic) has announced the addition of the "Non-Alcoholic Steatohepatitis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Non-Alcoholic Steatohepatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non-Alcoholic Steatohepatitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Cardax Pharmaceuticals, Inc. - Conatus Pharmaceuticals Inc. - Connexios Life Sciences Pvt. Ltd. - Cubist Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - Dr. Falk Pharma GmbH - Dynavax Technologies Corporation - Galectin Therapeutics, Inc. - Galmed International Ltd. - Genfit SA - Gilead Sciences, Inc. - Immuron Limited - Intercept Pharmaceuticals, Inc. - Isis Pharmaceuticals, Inc. - Jenrin Discovery, Inc. - Kadmon Corporation, LLC - Kissei Pharmaceutical Co., Ltd. - Kyorin Pharmaceutical Co., Ltd. - La Jolla Pharmaceutical Company - Mochida Pharmaceutical Co., Ltd. - Novo Nordisk A/S - Pharmaxis Limited - Phenex Pharmaceuticals AG - ProMetic Life Sciences Inc. - Raptor Pharmaceuticals Corp. - Shire Plc - Stelic Institute & Co. - Tobira Therapeutics, Inc. - Verva Pharmaceuticals Limited For more information visit http://www.researchandmarkets.com/research/np...nalcoholic
DVAX: 11.41 (-0.21), CNAT: 2.11 (-0.05), GALT: 2.73 (-0.14), NVO: 44.88 (-0.69), RPTP: 9.00 (+0.03), GILD: 81.37 (-0.15), SHPG: 203.05 (-1.17), ICPT: 166.23 (-4.24), TBRA: 39.11 (-0.39)
Dyslipidemia Therapeutics Pipeline Review 2015 - 35 Companies & 49 Drug Profiles
M2 - Mon Mar 02, 10:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/4qp3rm/dyslipidemia) has announced the addition of the "Dyslipidemia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Dyslipidemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dyslipidemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amgen Inc. - Arisaph Pharmaceuticals, Inc. - AstraZeneca PLC - Biocon Limited - Cadila Pharmaceuticals Ltd. - Cerenis Therapeutics Holding SA - Chong Kun Dang Pharmaceutical Corp. - CymaBay Therapeutics, Inc. - Daiichi Sankyo Company, Limited - Debiopharm International S.A. - Dezima Pharma BV - Dr. Reddy's Laboratories Limited - Genfit SA - GlaxoSmithKline plc - Hanmi Pharmaceuticals, Co. Ltd. - High Point Pharmaceuticals, LLC - Intas Pharmaceuticals Ltd. - JW Pharmaceutical Corporation - Kissei Pharmaceutical Co., Ltd. - Kotobuki Pharmaceutical Co., Ltd. - Kowa Company, Ltd. - Lipicard Technologies Limited - Merck & Co., Inc. - Nippon Chemiphar Co., Ltd. - Novartis AG - Pfizer Inc. - Sanofi - Takeda Pharmaceutical Company Limited - Torrent Pharmaceuticals Limited - Zydus Cadila Healthcare Limited For more information visit http://www.researchandmarkets.com/research/4q...slipidemia
PFE: 34.26 (+0.11), AMGN: 174.80 (-0.82), GSK: 43.42 (-0.16), AZN: 33.97 (-0.31), MRK: 62.96 (-0.06), CBAY: 1.95 (+0.03), NVS: 81.48 (-0.55)
Dyslipidemia Therapeutic Pipeline Companies and Drugs Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Tue Jan 27, 10:31AM CST
The report provides comprehensive information on the therapeutic development for Dyslipidemia. Dyslipidemia is an abnormal amount of cholesterol or fat in the blood. Dyslipidemia comes under consideration in many situations including diabetes, a common cause of lipidemia. Dyslipidemia is one of the major risk factors for cardiovascular disease in diabetes mellitus. Complete report is available at http://www.rnrmarketresearch.com/glaucoma-pip...eport.html .
PFE: 34.26 (+0.11), MRK: 62.96 (-0.06), AZN: 33.97 (-0.31), CBAY: 1.95 (+0.03), NVS: 81.48 (-0.55)
Constipation Therapeutic Pipeline Companies and Drugs Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Sun Jan 25, 10:30AM CST
The report "Constipation - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Constipation. Constipation is a disorder in which a person has severe problems defecating. Constipation occurs primarily because of the lack of the bowel movement in the body. The Lack of bowel movement in the body results in hardening of stools, swollen abdomen or abdominal pain. The reasons for constipation to occur in a body are inadequate water intake, less proportion of fiber in diet, irregularities in the pattern of diet. Not maintaining proper health and inadequacy in exercise can also lead to the abnormality during defecation & would mostly end with painful symptoms. Complete Report is Available @ http://www.rnrmarketresearch.com/constipation...eport.html .
SGYP: 5.61 (+0.03), SHPG: 203.05 (-1.17), AZN: 33.97 (-0.31), SCMP: 13.23 (-0.15), TEVA: 51.47 (+0.24)
Premature Labor (Tocolysis) Therapeutics Pipeline Review, H2 2014 - 5 Companies & 9 Drug Profiles
M2 - Fri Nov 07, 5:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/g6q4hn/premature_labor) has announced the addition of the "Premature Labor (Tocolysis) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Premature Labor (Tocolysis), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Premature Labor (Tocolysis) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - GlaxoSmithKline plc - Actavis plc - Kissei Pharmaceutical Co., Ltd. - PDC Biotech GmbH - ObsEva SA Drug Profiles - retosiban - bedoradrine sulfate - PDC-31 - Progesterone Vaginal Gel Second Generation - OBE-001 - Progesterone Based Formulation For Preterm Birth - OBE-002 - AT-814 - Drug for Postpartum Depression and Premature Labor For more information visit http://www.researchandmarkets.com/research/g6...ture_labor
GSK: 43.42 (-0.16)
